A cute recurrent pancreatitis (ARP) and chronic pancreatitis (CP) are poorly understood conditions of childhood. 1 Single-center studies estimate that 9% to 35% of children with acute pancreatitis (AP) have recurrent episodes, [2] [3] [4] [5] and the incidence of CP is approximately 0.5 per 100 000 persons per year in young adults. 6, 7 Factors that predispose children to recurrent episodes of AP and progression from ARP to CP are unknown. Although alcohol use and smoking have long been recognized as major risk factors for ARP and CP in adults, 8 they are uncommon in the pediatric age group. Recent single-center studies have identified several genetic risk factors in children with ARP or CP, 4, 5, [9] [10] [11] [12] [13] [14] including mutations in the following genes: cystic fibrosis transmembrane conductance regulator (CFTR), cationic trypsinogen (PRSS1), pancreatic secretory trypsin inhibitor (SPINK1), chymotrypsin C (CTRC), and carboxypeptidase 1 (CPA1). Other risk factors include obstructive, traumatic, infectious, and metabolic causes. 15, 16 Most of our current knowledge on ARP and CP comes from studies in adults. Because the etiologies of these diseases differ greatly between children and adults, applying the knowledge on the natural history and management of these diseases from adults to children may be inappropriate. The international, multicenter INSPPIRE (International Study Group of Pediatric Pancreatitis: In Search for a Cure) Consortium was created to address this issue by collecting data on the largest group of pediatric patients with ARP or CP to date. 10, 17 We have recently reported that genetic and obstructive factors are common in children with CP and that the associated disease burden is substantial. 10 In this study, we analyzed the demographic and clinical characteristics of children with ARP and CP with the goal of identifying the risk factors and disease burden.
Methods

Study Design and Participants
In this cross-sectional study from 15 institutions, demographic and clinical data were collected in patient/parent and physician questionnaires on children who fulfilled the criteria for ARP or CP and were aged 19 years or younger at the time of enrollment. 10, 17 Acute recurrent pancreatitis was defined as 2 episodes of AP along with resolution of pain (≥1 month between episodes) or as normalization of pancreatic enzyme levels and resolution of pain between episodes irrespective of time interval. 1 Diagnosis of CP required at least 1 of the following:
(1) abdominal pain plus imaging findings suggestive of chronic pancreatic damage; (2) exocrine pancreatic insufficiency and imaging findings suggestive of chronic pancreatic damage; or (3) endocrine pancreatic insufficiency and imaging findings suggestive of chronic pancreatic damage. 1 Information was entered into the REDCap (Research Electronic Data Capture) database from August 22, 2012, to February 8, 2015 , and represented baseline information of the INSPPIRE cohort. All centers obtained institutional review board approval or the equivalent for their country. Written informed consent and/or assent was obtained from all parents and children. Seventy-six of the patients with CP were described in a previous study. 10 We included patients with cystic fibrosis if they were pancreatic sufficient and having recurrent episodes of AP. Findings In this cross-sectional study of children with acute recurrent pancreatitis and chronic pancreatitis, pancreatitisassociated gene mutations were the most common risk factor. Children with chronic pancreatitis were mostly of non-Hispanic ethnicity, had PRSS1 or SPINK1 mutations, and had higher disease burden than those with acute recurrent pancreatitis.
Statistical Analysis
Results
Patient Characteristics
Meaning
The high disease burden in pediatric chronic pancreatitis underscores the importance of identifying predisposing factors for development of chronic pancreatitis in children.
Risk Factors
Risk factors were divided into 4 categories: genetic (CFTR, SPINK1, PRSS1, CTRC), obstructive, toxic/metabolic, and autoimmune. At least 1 risk factor was identified in 111 patients with ARP (72%) and 125 patients with CP (86%). The most common risk factors for development of ARP or CP were genetic and obstructive ( Table 2) .
At least 1 gene mutation in pancreatitis-related genes was found in 49 of 102 patients with ARP (48%) and 86 of 118 patients with CP (73%) (P < .001). Of the 53 patients with ARP in whom no mutations were identified, 18 were screened for 2 or fewer gene mutations. Of the 32 patients with CP who had no identified mutations, 6 were tested for fewer than 3 gene mutations.
The most common mutation identified in ARP was in CFTR (30 of 89 patients [34%]), and the most common mutation identified in CP was in PRSS1 (50 of 108 patients [46%]). Six children in the ARP group and 2 in the CP group had cystic fibrosis as determined by 2 CFTR disease-causing mutations and/or abnormal sweat chloride level. Children with PRSS1 or SPINK1 mutations were more likely to present with CP compared with ARP (PRSS1: OR = 4.20; 95% CI, 2.14-8.22; P < .001; and SPINK1: OR = 2.30; 95% CI, 1.03-5.13; P = .04).
Some children had more than 1 genetic risk factor. In children who had 3 or more genes tested, 8 of 84 patients with ARP (10%) and 17 of 112 patients with CP (15%) had more than 1 genetic risk factor. A combination of CFTR and SPINK1 mutations was most common (found in 5 children with ARP and 9 with CP). Obstructive risk factors were found in 33% of patients and toxic/metabolic factors were found in 21% (Table 2) Children with ARP or CP often had multiple risk factors. At least 1 risk factor was identified in 111 of 155 patients with ARP (72%), and 47 of 155 (30%) had multiple risk factors from different categories present. In the remaining 44 patients with ARP, only 8 were evaluated for all 4 genes and other risk factors. Of the 146 patients with CP, at least 1 risk factor was identified in 125 (86%), and 40 (27%) had multiple risk factors present. In the remaining 21 patients with CP, only 4 tested negative for all 4 genetic risk factors as well as other risk factors.
Burden of Disease
Pancreatitis-related abdominal pain was a major symptom in 81% of children with ARP or CP within the last year. The pain was mostly episodic in both groups ( Table 3) . Although constant and episodic pain scores were slightly higher in CP, the differences were not significant. [1] [2] [3] [4] , respectively; median difference, 2.0; 95% CI, 1.0-3.0; P < .001), but no differences were found Copyright 2016 American Medical Association. All rights reserved.
between groups for ED visits and hospitalizations within the past year (Table 3) . Children with CP missed a median of 2 days (IQR, 0-6 days) of school in the past month, whereas the median was 0 days (IQR, 0-5 days) for children with ARP; however, the difference was not statistically significant (median difference, 2 days; 95% CI, 0.2-3.8). Table 4 summarizes all imaging studies performed on children with ARP or CP. Overall, imaging studies were more frequently ordered for CP compared with ARP. Magnetic retrograde cholangiopancreatography was the most commonly used imaging modality; some children with CP had endoscopic retrograde cholangiopancreatography performed up to 9 times since their diagnosis. As expected, children with ARP had findings consistent with AP (pancreas enlargement, focal AP, inflammatory changes) compared with children with CP, who had evidence of persistent pancreatic injury (atrophy; calcifications; ductal irregularities, obstruction, dilatation, or stones; abnormal side branches).
Children with CP were more likely to receive medical, endoscopic, and surgical therapies compared with those who had ARP ( Table 5) . Medical therapy primarily consisted of pain medications and pancreatic enzymes. Acetaminophen and ibuprofen were the leading pain medications for ARP, while patients with CP used acetaminophen and hydrocodone bitartrate for pain. Therapeutic endoscopic retrograde cholangiopancreatography was performed in only 14% of children with ARP compared with 68% of those with CP. The most common type of surgery for pediatric ARP was cholecystectomy: The range of number of times ERCP was performed for a patient was 1 to 7 for children in the ARP group and 1 to 9 for those in the CP group. c The OR was computed based on the logit estimate that used a correction of 0.5 in every cell.
Discussion
This international, multicenter study is the largest characterized cohort of children with ARP and CP and, to our knowledge, it is the first observational study comparing a large number of children with ARP vs children with CP. Most children with CP described a history of ARP and tended to be older at the time of diagnosis compared with children with ARP, suggesting that ARP and CP are a disease continuum. A large proportion of children with ARP or CP had multiple risk factors, suggesting the multifactorial nature of these conditions. The clustering of PRSS1 or SPINK1 mutations in children with CP raises the possibility that these gene mutations are important risk factors for progression from ARP to CP in the pediatric population. The disease burden was higher in CP compared with ARP, suggesting the importance of identifying early interventions to prevent or delay progression from ARP to CP. Among the risk factors analyzed, an underlying genetic predisposition was most commonly found in our patients, almost 50% in ARP and approaching 75% in CP. Our findings agree with previous reports showing genetic mutations as common risk factors in children with ARP or CP. 9, 12, 14, 18, 19 We may be underestimating the impact of gene mutations as risk factors for ARP or CP because we do not have analysis of the most commonly tested genes (PRSS1, CFTR, SPINK1, CTRC) for every patient in the database, as gene testing for INSPPIRE patients was at the physician's discretion. Some of the newly discovered pancreatitis susceptibility genes also were not tested, as tests for them were not commercially available (CPA1, CLDN2, CEL, CEL-HYB). 11, [20] [21] [22] To our knowledge, the natural history of pediatric pancreatitis has not been systematically investigated in children. Most of the data in adults that support progression of ARP to CP come from hereditary pancreatitis populations. 23, 24 Indeed, pancreatitis follows a severe course in patients with PRSS1 mutations (particularly R122H and N29I) with first episodes by approximately 10 years of age and progression to CP within the subsequent decade. Our findings support the hypothesis that PRSS1 is involved in progression from ARP to CP in children as well. The role of SPINK1 mutations as a cause of pancreatitis is debated because these mutations can be found in 1% to 3% of the general population. We report a higher percentage of SPINK1 mutations in the INSPPIRE cohort (13% of those with ARP; 25% of those with CP). Similarly, SPINK1 N34S mutations have been found in approximately 25% of children with ARP or CP, a higher percentage compared with the general population. 12, 19, 25 In addition, people with SPINK1 mutations are more prone to ARP or CP if mutations in other pancreatitisrelevant genes are also present (ie, PRSS1, CFTR, CTRC), with up to 900-fold increased risk by having both CFTR and SPINK1 It was associated with decreased frequency in children with PRSS1 mutations. Most studies reporting association of PD with ARP or CP, similar to this study, are based on symptomatic patients who had imaging studies done for the evaluation of pancreatitis. The involvement of PD in the pathogenesis of ARP or CP needs to be further studied. We found that a large subset of children with ARP or CP had more than 1 identifiable risk factor, including patients with more than 1 risk factor in a single category (genetic factors) and patients with a combination of factors across categories. Our observations are consistent with previous studies suggesting that the pathogenesis of ARP or CP is multifactorial.
We observed that most of the children with ARP and CP were white and CP was less common in patients with Hispanic ethnicity. This is likely due to genetic mutations found in white individuals and not referral bias in our study. In a recent analysis of 2 large national databases that included more than 1.5 million hospitalized US children, CP was also found more commonly in white patients. 30 The possible reduced risk noted in our pediatric Hispanic population may be explained by the lower prevalence of PRSS1 and SPINK1 mutations in this group. Most of the children in our study reported pancreatitisrelated pain within the previous year; the pain was chronic in one-third of the patients. The disease burden was higher in the CP group compared with the ARP group (significantly more ED visits and hospitalizations; significantly more medical, endoscopic, and surgical therapies; and more missed school days). Pancreatitis causes a serious burden on the health care system, with AP being the top gastrointestinal cause for admission in adults. 31 With increasing incidence of AP in childhood, 32, 33 we expect that the disease burden in our cohort is substantial. We were surprised by the large number of children with AIP in our cohort. The diagnosis of AIP in the medical literature is limited to few case reports. 34 As previously reported, most children with AIP in our study had type 2. Our future goal is to develop diagnostic and therapeutic criteria for pediatric AIP. These guidelines will be aimed to better phenotype children in our database as well as to bring a unifying definition to this disease. Our study has several limitations. The prevalence of genetic predisposing factors was underestimated because not every patient underwent genetic testing and when they did, it was not always complete. Newly identified pancreatitisassociated genes could not be identified in our population, as tests are not commercially available. Moving forward, we plan to test INSPPIRE patients for all pancreatitis-relevant genes. While we acknowledge a potential referral bias from large referral centers in our study, we note that a center that performed most islet cell transplants (University of Minnesota) contributed approximately 10% to our cohort (eTable 1 in the Supplement). The analysis of children with ARP or CP was done at the time of enrollment; therefore, assessment of risk factors could not be done over time as children progressed from ARP to CP. Nevertheless, the large number of wellphenotyped patients with ARP or CP allowed us to compare the characteristics of these children. Our study is underpowered to study the role of cholecystectomy on relieving recurrent disease. Prospective data collection is more likely to shed light on this question. Through a prospective registry of longitudinal clinical data, INSPPIRE aims to determine the natural course of pediatric ARP and CP and identify risk factors for the progression to CP.
Conclusions
Pancreatitis-associated gene mutations are the most common risk factors in children with ARP or CP, and multiple risk factors are usually coexistent. The socioeconomic burden of disease is significant given the presence of pain, health care visits, and number of diagnostic tests performed. Further work will focus on analyzing the impact of genetic and other risk factors on the natural history of pediatric pancreatitis and its sequelae and developing a standardized approach to the evaluation of children with ARP or CP.
